申请人:Pfizer Inc.
公开号:EP2591787A1
公开(公告)日:2013-05-15
Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5' TCGTCGTTTTCGGCGCGCGCCGT 3' (SEQ ID NO: 1), in which each C is unmethylated and 3' refers to the 3' end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-gamma. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.
本研究公开了免疫刺激寡核苷酸,它包含一个 CpG 免疫刺激基序和一个能够形成二级结构(包括体外和体内的双链和高阶结构)的二级基序。它们包括核酸或其药学上可接受的盐,其碱基序列包括 5' TCGTCGTTTTCGGCGCGCGCCGT 3' (SEQ ID NO: 1),其中每个 C 是未甲基化的,3' 是指核酸的 3' 端。寡核苷酸可激活 B 细胞和 NK 细胞,诱导 I 型干扰素和γ 干扰素的表达。寡核苷酸可用于治疗各种疾病,包括过敏、哮喘、感染和癌症。除了用作单药和联合疗法外,所公开的寡核苷酸还可用作疫苗佐剂。